

03-12-04

GAU 1642

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of
PARKER, et al.

Examiner: HELMS, Larry R.

Art Unit: 1642

Application No.: 09/719,758

Filed: **January 4, 2002**

Title: **MONOCLONAL ANTIBODIES
DIRECTED AGAINST THE G3BP
PROTEIN AND USES**

I hereby certify that this correspondence is being
deposited with the United States Postal Service as
Express Mail in an envelope addressed to
Commissioner for Patents, P.O. Box 1450, Alexandria,
VA 22313-1450, on

11 March 2004
Date of Deposit
Joel B. German, Esq.
Signature
EL 964841643 US
Express Mail Certificate


RESPONSE TO EXAMINER'S REQUEST

United States Patent and Trademark Office
Attn: Examiner Larry R. Helms
Group Art Unit: 1642
Mail Stop: Patent Application
P.O. Box 1450
Alexandria, VA 22313-1450

Examiner Helms,

Per your request, I'm submitting both paper copy and computer readable form of the
Sequence Listing in the above-mentioned patent application.

Respectfully submitted,


Joel B. German, Reg. No. 48,676
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-3444
Telefax (908) 231-2626

Aventis Docket No. USST98017 US PCT



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re Application of
PARKER, et al.

Examiner: HELMS, Larry R.

Art Unit: 1642

Application No.: 09/719,758

Filed: **January 4, 2002**

Title: **MONOCLONAL ANTIBODIES
DIRECTED AGAINST THE G3BP
PROTEIN AND USES**

I hereby certify that this correspondence is being
deposited with the United States Postal Service as
Express Mail in an envelope addressed to
Commissioner for Patents, P.O. Box 1450, Alexandria,
VA 22313-1450, on

11 March 2004

Date of Deposit

Signature

EL 964841643 US

Express Mail No.

STATEMENT REGARDING CONTENT OF PAPER AND COMPUTER READABLE
COPIES PURSUANT TO 37 C.F.R. 1.821 (f)

United States Patent and Trademark Office
Attn: Examiner Larry R. Helms
Group Art Unit: 1642
Mail Stop: Patent Application
P.O. Box 1450
Alexandria, VA 22313-1450

The undersigned states that the content of the nucleotide and/or amino acid sequences set forth in the enclosed substitute pages of the "Sequence Listing" and the computer readable copies required by 37 C.F.R. 1.821 (e) submitted herewith are the same; and (2) the content of the substitute copy of the Sequence Listing and the computer readable copies required by 37 C.F.R. 1.821 (e) contain no new matter. Support for the Amendments can be found in the application as filed.

Respectfully submitted,

Joel B. German, Reg. No. 48,676
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, New Jersey 08807-0800
Telephone (908) 231-3444
Telefax (908) 231-2626

Aventis Docket No. USST98017